Drug survival of systemic and biologic treatments for moderate-to-severe atopic dermatitis in adults: a multicenter retrospective observational study.

Drug survival of systemic and biologic treatments for moderate-to-severe atopic dermatitis in adults: a multicenter retrospective observational study. Br J Dermatol. 2020 Jul 30;: Authors: Pereyra-Rodriguez JJ, Domínguez-Cruz J, Ruiz-Villaverde R, Silvestre JF, Galán M, Curto L, Figueras I, Serra-Baldrich E, Armario-Hita JC Abstract Drug survival is a real-life reflection of drug performance in routine medical practice and measures the patient's persistence under a given treatment. Survival of systemic treatment of atopic dermatitis (AD) has been evaluated in previous analyses in routine clinical practice. Recently, dupilumab, a fully human monoclonal antibody that targets the IL-4 receptor α, has been approved for the treatment of moderate to severe AD. PMID: 32730674 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research